Home » Topics » Dermatologic, BioWorld Science

Dermatologic, BioWorld Science
RSS

Velac enters phase III development program for acne

Jan. 9, 2003

Proof of concept established in patients for Arachnova's product for dermatitis

Jan. 9, 2003

Finacea approved for topical treatment of rosacea

Jan. 9, 2003

BMS claims new antagonists of LFA-1 and Mac-1/ICAM interaction

Jan. 8, 2003

Galderma describes new series of vitamin D analogues for skin disorders

Jan. 7, 2003

Zindaclin receives further E.U. approvals

Jan. 7, 2003

Genentech and Xoma submit BLA for FDA approval of Raptiva

Jan. 3, 2003

Olux approved for treatment of psoriasis

Jan. 3, 2003

Phase I trial of BI-K0376 completes enrollment

Dec. 30, 2002

Phase II trial of VX-148 in psoriasis patients commences in Iceland

Dec. 27, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...